clonidine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihypertensives, clonidine derivatives 704 4205-90-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clonidine
  • clonidine hydrochloride
  • clonidine HCl
An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
  • Molecular weight: 230.09
  • Formula: C9H9Cl2N3
  • CLOGP: 1.73
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 36.42
  • ALOGS: -2.68
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.45 mg O
0.45 mg P
0.10 mg O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.17 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
EoM (Fraction excreted unchanged in urine) 62 % Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 3.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.56 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 3, 1974 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 1564.99 40.95 384 1773 20650 2335278
Hypotension 539.87 40.95 187 1970 32249 2323679
Toxicity to various agents 510.92 40.95 180 1977 32574 2323354
Overdose 389.46 40.95 130 2027 19777 2336151
Bradycardia 349.92 40.95 102 2055 9879 2346049
Poisoning 317.26 40.95 73 2084 2747 2353181
Drug withdrawal syndrome 257.75 40.95 74 2083 6747 2349181
Hypertension 242.30 40.95 100 2057 27261 2328667
Drug hypersensitivity 241.65 40.95 117 2040 46526 2309402
Sinus bradycardia 223.05 40.95 52 2105 2064 2353864
Temperature regulation disorder 218.68 40.95 34 2123 127 2355801
Blood pressure increased 213.18 40.95 80 2077 16906 2339022
Somnolence 201.48 40.95 84 2073 23401 2332527
Drug ineffective 189.63 40.95 131 2026 101493 2254435
Pain 183.31 40.95 107 2050 61750 2294178
Respiratory arrest 180.59 40.95 55 2102 6123 2349805
Cardiac arrest 178.80 40.95 68 2089 14862 2341066
Product adhesion issue 176.37 40.95 39 2118 1213 2354715
Death 175.62 40.95 115 2042 81353 2274575
Mental status changes 168.72 40.95 51 2106 5531 2350397
Cardio-respiratory arrest 167.20 40.95 57 2100 9089 2346839
Food allergy 166.24 40.95 33 2124 598 2355330
Coeliac disease 162.92 40.95 34 2123 798 2355130
Sedation 161.12 40.95 44 2113 3318 2352610
Immunodeficiency 148.68 40.95 33 2124 1043 2354885
Medication error 143.20 40.95 46 2111 6085 2349843
Bursitis 139.81 40.95 35 2122 1873 2354055
Hyperhidrosis 128.06 40.95 54 2103 15368 2340560
Blood pressure inadequately controlled 121.02 40.95 27 2130 873 2355055
Headache 120.59 40.95 91 2066 80088 2275840
Lethargy 119.80 40.95 44 2113 8686 2347242
Depressed level of consciousness 118.09 40.95 42 2115 7562 2348366
Hypertensive crisis 116.22 40.95 32 2125 2481 2353447
Intentional overdose 115.63 40.95 46 2111 11275 2344653
Exposure during pregnancy 114.28 40.95 58 2099 25161 2330767
Application site rash 102.30 40.95 22 2135 597 2355331
Fluid retention 102.16 40.95 37 2120 7009 2348919
Nodal rhythm 100.71 40.95 20 2137 362 2355566
Rash erythematous 100.36 40.95 35 2122 5941 2349987
Hypersensitivity 100.30 40.95 52 2105 23541 2332387
Application site pruritus 99.76 40.95 23 2134 863 2355065
Withdrawal hypertension 96.37 40.95 14 2143 28 2355900
Suicide attempt 95.22 40.95 40 2117 11242 2344686
Fatigue 90.71 40.95 79 2078 84794 2271134
Product substitution issue 90.18 40.95 31 2126 5038 2350890
Constipation 89.98 40.95 47 2110 21582 2334346
Asthma 88.46 40.95 38 2119 11276 2344652
Unresponsive to stimuli 87.44 40.95 30 2127 4846 2351082
Apnoea 84.27 40.95 22 2135 1389 2354539
Back pain 83.42 40.95 51 2106 31608 2324320
Hypertensive encephalopathy 82.90 40.95 15 2142 160 2355768
Application site erythema 81.49 40.95 21 2136 1259 2354669
Urinary incontinence 79.63 40.95 27 2130 4206 2351722
Confusional state 79.30 40.95 45 2112 24299 2331629
Acute motor-sensory axonal neuropathy 78.18 40.95 12 2145 40 2355888
Hepatic enzyme increased 76.86 40.95 33 2124 9769 2346159
Upper respiratory tract infection 76.72 40.95 32 2125 8819 2347109
Asthenia 76.35 40.95 56 2101 46870 2309058
Erythema 70.01 40.95 42 2115 25117 2330811
Dry mouth 68.71 40.95 29 2128 8224 2347704
Miosis 67.89 40.95 18 2139 1206 2354722
Heart rate decreased 67.38 40.95 23 2134 3653 2352275
Dizziness 67.35 40.95 57 2100 58608 2297320
Drug abuse 67.31 40.95 32 2125 11994 2343934
Left ventricular hypertrophy 67.10 40.95 16 2141 695 2355233
Nausea 66.81 40.95 76 2081 112113 2243815
Loss of consciousness 64.62 40.95 36 2121 18731 2337197
Muscular weakness 63.68 40.95 33 2124 14864 2341064
Medical device site pain 63.33 40.95 10 2147 42 2355886
Delirium 63.08 40.95 24 2133 5199 2350729
Hypothermia 62.11 40.95 19 2138 2129 2353799
Intentional product misuse 61.64 40.95 28 2129 9461 2346467
Syncope 59.81 40.95 33 2124 16842 2339086
Accidental exposure to product by child 58.95 40.95 14 2143 597 2355331
Presyncope 58.94 40.95 21 2136 3782 2352146
Fall 58.65 40.95 48 2109 47051 2308877
Blood pressure decreased 56.05 40.95 26 2131 9210 2346718
Rheumatoid arthritis 55.93 40.95 33 2124 19107 2336821
Exposure via ingestion 55.41 40.95 14 2143 774 2355154
Dysarthria 55.31 40.95 23 2134 6279 2349649
Agitation 54.57 40.95 27 2130 11024 2344904
Vomiting 52.08 40.95 54 2103 71548 2284380
Sinus arrhythmia 51.87 40.95 11 2146 278 2355650
Application site irritation 51.52 40.95 12 2145 470 2355458
Retrograde amnesia 49.73 40.95 9 2148 96 2355832
Anxiety 47.55 40.95 35 2122 29324 2326604
Malignant hypertension 47.53 40.95 10 2147 243 2355685
Atrioventricular block second degree 47.46 40.95 12 2145 665 2355263
Product quality issue 46.28 40.95 24 2133 10805 2345123
Adverse drug reaction 46.19 40.95 22 2135 8261 2347667
Pulmonary oedema 45.51 40.95 21 2136 7342 2348586
Respiratory depression 45.38 40.95 15 2142 2155 2353773
Infusion site mass 44.23 40.95 8 2149 85 2355843
Hypoaesthesia 44.22 40.95 29 2128 20186 2335742
Seizure 43.79 40.95 31 2126 24435 2331493
Oliguria 43.50 40.95 13 2144 1344 2354584
Accidental overdose 43.48 40.95 17 2140 3955 2351973
Pulse absent 43.32 40.95 12 2145 947 2354981
Bundle branch block left 43.02 40.95 12 2145 972 2354956
Coma 41.38 40.95 21 2136 9035 2346893
Systolic dysfunction 41.19 40.95 8 2149 128 2355800
Mydriasis 41.10 40.95 14 2143 2205 2353723

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 1023.77 42.19 279 1536 16033 1728933
Hypotension 460.88 42.19 177 1638 29477 1715489
Toxicity to various agents 374.83 42.19 152 1663 28989 1715977
Bradycardia 373.88 42.19 117 1698 10417 1734549
Drug withdrawal syndrome 250.20 42.19 71 1744 4454 1740512
Drug ineffective 224.38 42.19 138 1677 63663 1681303
Hypertension 223.40 42.19 94 1721 19354 1725612
Overdose 202.64 42.19 84 1731 16617 1728349
Sedation 199.52 42.19 56 1759 3361 1741605
Miosis 172.41 42.19 42 1773 1436 1743530
Aggression 170.62 42.19 61 1754 8054 1736912
Cardiac arrest 166.04 42.19 72 1743 15858 1729108
Somnolence 165.86 42.19 73 1742 16666 1728300
Respiratory arrest 150.00 42.19 51 1764 5788 1739178
Agitation 148.94 42.19 60 1755 10966 1734000
Pain 136.36 42.19 74 1741 26583 1718383
Lethargy 128.57 42.19 48 1767 7136 1737830
Withdrawal hypertension 128.56 42.19 18 1797 12 1744954
Blood pressure increased 126.39 42.19 53 1762 10700 1734266
Sinus bradycardia 123.31 42.19 34 1781 1899 1743067
Poisoning 123.01 42.19 36 1779 2496 1742470
Dizziness 121.42 42.19 75 1740 34286 1710680
Product adhesion issue 112.98 42.19 23 1792 335 1744631
Syncope 112.35 42.19 53 1762 14116 1730850
Product substitution issue 109.61 42.19 35 1780 3251 1741715
Intentional overdose 97.43 42.19 40 1775 7630 1737336
Depressed level of consciousness 92.73 42.19 37 1778 6555 1738411
Hypertensive crisis 88.83 42.19 25 1790 1502 1743464
Mental status changes 88.59 42.19 35 1780 6040 1738926
Decreased eye contact 87.24 42.19 14 1801 44 1744922
Oppositional defiant disorder 84.61 42.19 14 1801 56 1744910
Cardio-respiratory arrest 83.64 42.19 38 1777 9255 1735711
Blood pressure decreased 80.81 42.19 35 1780 7611 1737355
Accidental overdose 75.02 42.19 28 1787 4136 1740830
Withdrawal syndrome 74.73 42.19 24 1791 2264 1742702
Unresponsive to stimuli 68.60 42.19 27 1788 4602 1740364
Speech disorder 65.55 42.19 26 1789 4522 1740444
Bruxism 63.50 42.19 14 1801 303 1744663
Respiratory depression 62.99 42.19 21 1794 2226 1742740
Dyskinesia 62.70 42.19 24 1791 3795 1741171
Hypotonia 61.81 42.19 19 1796 1551 1743415
Off label use 61.37 42.19 52 1763 38519 1706447
Medication error 61.06 42.19 25 1790 4718 1740248
Insomnia 60.96 42.19 37 1778 16239 1728727
Gastrointestinal tract mucosal pigmentation 60.81 42.19 9 1806 13 1744953
Tachycardia 58.61 42.19 33 1782 12595 1732371
Psychomotor hyperactivity 58.31 42.19 19 1796 1874 1743092
Drug interaction 57.86 42.19 44 1771 27914 1717052
Respiratory acidosis 57.52 42.19 15 1800 673 1744293
Sydenham's chorea 57.32 42.19 8 1807 5 1744961
Metabolic alkalosis 56.21 42.19 12 1803 222 1744744
Device failure 55.78 42.19 15 1800 758 1744208
Heart rate decreased 54.66 42.19 20 1795 2789 1742177
Death 53.98 42.19 71 1744 87372 1657594
Homicidal ideation 53.92 42.19 14 1801 617 1744349
Atrioventricular block first degree 52.94 42.19 15 1800 921 1744045
Haematuria 52.86 42.19 26 1789 7534 1737432
Suicidal ideation 52.81 42.19 27 1788 8491 1736475
Hyperhidrosis 50.91 42.19 30 1785 12458 1732508
Irritability 50.91 42.19 23 1792 5509 1739457
Sleep disorder 50.87 42.19 21 1794 4042 1740924
Suicide attempt 50.46 42.19 25 1790 7356 1737610
Respiratory rate decreased 49.20 42.19 12 1803 409 1744557
Fatigue 49.16 42.19 52 1763 50729 1694237
Application site rash 48.96 42.19 11 1804 260 1744706
Nausea 48.80 42.19 52 1763 51144 1693822
Intentional self-injury 48.21 42.19 18 1797 2655 1742311
Choreoathetosis 48.03 42.19 10 1805 163 1744803
Electrocardiogram QT prolonged 47.70 42.19 22 1793 5523 1739443
Affective disorder 47.45 42.19 13 1802 705 1744261
Anxiety 47.33 42.19 31 1784 15496 1729470
Accidental exposure to product by child 46.51 42.19 13 1802 759 1744207
Loss of consciousness 46.07 42.19 30 1785 14845 1730121
Coordination abnormal 46.00 42.19 15 1800 1482 1743484
Headache 45.90 42.19 42 1773 34334 1710632
Drug hypersensitivity 45.60 42.19 30 1785 15105 1729861

Pharmacologic Action:

SourceCodeDescription
ATC C02AC01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Imidazoline receptor agonists
ATC N02CX02 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Other antimigraine preparations
ATC S01EA04 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Sympathomimetics in glaucoma therapy1)
ATC C02LC01 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Imidazoline receptor agonists in combination with diuretics
ATC C02LC51 CARDIOVASCULAR SYSTEM
ANTIHYPERTENSIVES
ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION
Imidazoline receptor agonists in combination with diuretics
MeSH PA D018663 Adrenergic Agents
MeSH PA D000322 Adrenergic Agonists
MeSH PA D058647 Adrenergic alpha-2 Receptor Agonists
MeSH PA D000316 Adrenergic alpha-Agonists
FDA MoA N0000009918 Adrenergic alpha2-Agonists
FDA EPC N0000175554 Central alpha-2 Adrenergic Agonist
MeSH PA D000700 Analgesics
CHEBI has role CHEBI:66991 sympatholytic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35481 non-narcotic analgesic
CHEBI has role CHEBI:35569 alpha-adrenergic agonist
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
MeSH PA D013565 Sympatholytics

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763
Severe pain indication 76948002
Open-angle glaucoma indication 84494001 DOID:1067
Attention deficit hyperactivity disorder indication 406506008
Increased Intraocular Pressure after Ocular Procedure indication
Ocular hypertension off-label use 4210003 DOID:9282
Gilles de la Tourette's syndrome off-label use 5158005 DOID:11119
Diarrhea off-label use 62315008
Opioid withdrawal off-label use 87132004
Menopausal flushing off-label use 198436008
Smoking cessation assistance off-label use 384742004
Nicotine Withdrawal Symptoms off-label use
Anuria contraindication 2472002 DOID:2983
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Hyperuricemia contraindication 35885006 DOID:1920
Hypokalemia contraindication 43339004
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Tear film insufficiency contraindication 46152009
End stage renal disease contraindication 46177005 DOID:784
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Bradycardia contraindication 48867003
Sinus bradycardia contraindication 49710005
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Sympathectomy contraindication 57071006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Blood coagulation disorder contraindication 64779008 DOID:1247
Hypercalcemia contraindication 66931009 DOID:12678
Hypochloremic alkalosis contraindication 70134007
Decreased respiratory function contraindication 80954004
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Gout contraindication 90560007 DOID:13189
Magnetic resonance imaging contraindication 113091000
Perioperative care contraindication 133897009
Hypomagnesemia contraindication 190855004
Acute pancreatitis contraindication 197456007 DOID:2913
Atrioventricular block contraindication 233917008 DOID:0050820
Labor pain contraindication 247412007
Raynaud's phenomenon contraindication 266261006
Syncope contraindication 271594007
Surgical procedure contraindication 387713003
Chronic myocardial ischemia contraindication 413844008 DOID:3393
Myocardial ischemia contraindication 414795007 DOID:3393
Inflammatory dermatosis contraindication 703938007
Vagal Reflex Bradycardia contraindication
Severe Cardiopulmonary Disease contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.5 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Alpha-2B adrenergic receptor GPCR AGONIST Ki 7.50 CHEMBL CHEMBL
Alpha-2A adrenergic receptor GPCR AGONIST Ki 8.42 CHEMBL CHEMBL
Alpha-2C adrenergic receptor GPCR AGONIST EC50 6.70 WOMBAT-PK CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.65 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 4.48 CHEMBL
Nischarin Membrane receptor Ki 8.05 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.49 CHEMBL
Solute carrier family 22 member 2 Transporter IC50 4.80 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 6.50 PDSP
Alpha-1B adrenergic receptor GPCR Ki 6.50 PDSP
Alpha-1A adrenergic receptor GPCR Kd 6.59 CHEMBL
Adrenergic receptor alpha-2 GPCR Ki 8.82 CHEMBL
Alpha-2A adrenergic receptor GPCR IC50 8.70 CHEMBL
Nischarin Unclassified Ki 6.95 CHEMBL
Alpha-2B adrenergic receptor GPCR Ki 8.08 CHEMBL
Beta-1 adrenergic receptor GPCR Kd 4.40 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 9.41 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.27 CHEMBL
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Unclassified BLOCKER IC50 5 IUPHAR
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 Ion channel BLOCKER IC50 5.10 IUPHAR
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Ion channel BLOCKER IC50 4.40 IUPHAR
Alpha-1D adrenergic receptor GPCR AGONIST Ki 6.90 IUPHAR
Alpha-1B adrenergic receptor GPCR Ki 5.99 DRUG MATRIX

External reference:

IDSource
D003000 MESH_DESCRIPTOR_UI
4017850 VUID
N0000146207 NUI
C0009014 UMLSCUI
D00281 KEGG_DRUG
62782004 SNOMEDCT_US
4017850 VANDF
004495 NDDF
2599 RXNORM
d00044 MMSL
372805007 SNOMEDCT_US
4478 MMSL
2803 PUBCHEM_CID
CHEBI:46631 CHEBI
CHEMBL134 ChEMBL_ID
DB00575 DRUGBANK_ID
CHEMBL1705 ChEMBL_ID
MN3L5RMN02 UNII
2624 INN_ID
CLU PDB_CHEM_ID
4205-91-8 SECONDARY_CAS_RN
516 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9723 INJECTION, SOLUTION 500 ug INTRAVENOUS ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-9724 INJECTION, SOLUTION 100 ug INTRAVENOUS ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2127 TABLET 0.10 mg ORAL ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2128 TABLET 0.20 mg ORAL ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-2129 TABLET 0.30 mg ORAL ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-4241 TABLET, EXTENDED RELEASE 0.10 mg ORAL ANDA 18 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0228-4242 TABLET, EXTENDED RELEASE 0.20 mg ORAL ANDA 18 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0152 TABLET 0.10 mg ORAL ANDA 11 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0186 TABLET 0.20 mg ORAL ANDA 11 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-0199 TABLET 0.30 mg ORAL ANDA 11 sections
Clonidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0871 PATCH 0.10 mg TRANSDERMAL ANDA 14 sections
Clonidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0872 PATCH 0.20 mg TRANSDERMAL ANDA 14 sections
Clonidine HUMAN PRESCRIPTION DRUG LABEL 1 0378-0873 PATCH 0.30 mg TRANSDERMAL ANDA 14 sections
Clonidine transdermal system HUMAN PRESCRIPTION DRUG LABEL 1 0591-3508 PATCH 0.10 mg TRANSDERMAL ANDA 13 sections
Clonidine transdermal system HUMAN PRESCRIPTION DRUG LABEL 1 0591-3509 PATCH 0.20 mg TRANSDERMAL ANDA 13 sections
Clonidine transdermal system HUMAN PRESCRIPTION DRUG LABEL 1 0591-3510 PATCH 0.30 mg TRANSDERMAL ANDA 13 sections
Catapres HUMAN PRESCRIPTION DRUG LABEL 1 0597-0006 TABLET 0.10 mg ORAL NDA 12 sections
Catapres HUMAN PRESCRIPTION DRUG LABEL 1 0597-0007 TABLET 0.20 mg ORAL NDA 12 sections
Catapres HUMAN PRESCRIPTION DRUG LABEL 1 0597-0011 TABLET 0.30 mg ORAL NDA 12 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0031 PATCH 0.10 mg TRANSDERMAL NDA 14 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0032 PATCH 0.20 mg TRANSDERMAL NDA 14 sections
Catapres-TTS HUMAN PRESCRIPTION DRUG LABEL 1 0597-0033 PATCH 0.30 mg TRANSDERMAL NDA 14 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-2572 TABLET 0.10 mg ORAL ANDA 11 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-2574 TABLET 0.30 mg ORAL ANDA 11 sections
clonidine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7947 TABLET 0.10 mg ORAL ANDA 12 sections
clonidine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7948 TABLET 0.20 mg ORAL ANDA 12 sections
clonidine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8164 TABLET 0.30 mg ORAL ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-8272 TABLET 0.20 mg ORAL ANDA 12 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0777 TABLET, EXTENDED RELEASE 0.10 mg ORAL ANDA 19 sections
Clonidine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-5656 TABLET 0.10 mg ORAL ANDA 12 sections